Alzheimer's Disease Trial, Recruiting NCT07260253 Sponsor: Maya Henry Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07260253
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with primary progressive aphasia (PPA), specifically the logopenic variant — a condition that affects language and speech
  • People who score 15 or higher on a standard memory and thinking test called the Mini-Mental State Examination
  • People who have adequate hearing and vision, including with the help of hearing aids or glasses if needed
  • People who are able to travel to the research site and have an MRI brain scan
  • People who have access to high-speed internet and have basic experience using a computer and the internet
  • People who speak English fluently
  • People who have a "study partner" (such as a family member or carer) who is willing to also enroll in the study, attend training at the research site, and join online video meetings when needed

Who may not be able to join:

  • People whose speech and language difficulties are better explained by a different neurological condition
  • People who do not meet the specific diagnostic criteria for the logopenic variant of PPA
  • People who score below 15 on the Mini-Mental State Examination
  • People who do not have a study partner available to participate alongside them
  • People who have certain health conditions or devices that make brain stimulation (tDCS) or MRI scans unsafe, including: a history of seizures, head injury, or skull surgery; a history of severe or frequent migraines; any metal implants in the head; a pacemaker or similar heart device; chronic skin conditions; or current pregnancy
  • People who have a history of stroke, epilepsy, or significant brain injury

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maya L Henry, PhD, University of Texas at Austin

Phone: 512-471-3420

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Maya Henry
Registry
ClinicalTrials.gov
Start date
15 April 2026
Est. completion
1 May 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in spoken naming

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov